Methamphetamine hcl

Adult wild-type and TH-HI mice were randomly assigned to treatment groups that would receive 4 injections of 0.9% saline, 5.0 mg/kg or 10 mg/kg of (+)-Methamphetamine HCl (Sigma; dissolved in 0.9% saline). Treatments were administered through a subcutaneous injection, as previously described (Lohr et al. 2015 (link)). The first dose was administered 60 minutes after baseline core body temperature was measured using a rectal thermometer. Three additional equivalent doses followed, administered at 2-hour intervals (i.e. 180, 300, and 420 minutes following the initial injection). Core body temperature was measured at the time of each injection. Mice were sacrificed by rapid decapitation 48 hours following the first injection, and the striatum was dissected and flash-frozen in liquid nitrogen for protein analyses by Western blot, using standard methods described above. The experimenter was blinded until the point of statistical analyses.

Methamphetamine HCl (Sigma, St Louis, MO) was dissolved in 0.9%
sterile saline. For both systemic and intracranial administrations, oxytocin
(Cell Sciences, Canton, MA) was dissolved in 0.9% sterile saline, and
the mGluR2/3 antagonist LY341495 (Tocris bioscience, Bristol, UK) was first
dissolved in HCl and then saline. All drug doses were derived from previous work
from our laboratory and others. For systemic injections oxytocin was
administered at 1 mg/kg (Cox et al.,
2013, Zhou et al., 2015 ; Leong et al., 2016 (link)) and LY341495 was
injected at 1 mg/kg (Scofield et al.,
2015; Li et al., 2010). For intracranial administration, oxytocin was
infused at a concentration of 0.6nmol/0.25µl/side (Baracz et al., 2012 ; Cox et
al., 2017). LY341495 was infused at a concentration of
1.3nmol/0.25µl/side based on a range of two efficient doses (Kim
et al, 2015; Richard and Berridge, 2011). Micro infusions
were made by inserting a 33-gauge stainless steel injector (Plastics One,
Roanoke, VA) into the guide cannulae. The injector was connected to a
polyethylene tube (PE-20) and fitted to a 1 µl Hamilton syringe
(Hamilton, NV, USA). Each rat received two consecutive microinjections of either
LY341495 or vehicle followed by oxytocin or saline over a 1 min period.
Injectors were left in place an additional minute to allow for diffusion.